Gregory M. Lubiniecki

机构：Merck & Co., Inc., Rahway, NJ, USA (United States)

发表论文 69 篇 · 总被引 33713 次 · h-index 32

代表论文

• Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer (2018 · New England Journal of Medicine · 被引 3686)
• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019 · The Lancet · 被引 3377)
• Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial (2017 · The Lancet Oncology · 被引 351)
• Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study (2020 · Journal of Clinical Oncology · 被引 284)
• Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial (2017 · Annals of Oncology · 被引 240)
• Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. (2018 · Journal of Clinical Oncology · 被引 192)